1. Home
  2. MTC vs ACET Comparison

MTC vs ACET Comparison

Compare MTC & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MTC

MMTec Inc.

HOLD

Current Price

$6.96

Market Cap

71.8M

Sector

Technology

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$6.26

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTC
ACET
Founded
2015
1947
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
71.8M
69.6M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
MTC
ACET
Price
$6.96
$6.26
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$48.33
AVG Volume (30 Days)
37.0K
102.3K
Earning Date
12-13-2024
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.46
52 Week High
$7.00
$9.05

Technical Indicators

Market Signals
Indicator
MTC
ACET
Relative Strength Index (RSI) 66.70 42.48
Support Level $0.74 $6.21
Resistance Level $7.00 $8.34
Average True Range (ATR) 0.77 0.38
MACD -0.00 -0.01
Stochastic Oscillator 97.62 34.29

Price Performance

Historical Comparison
MTC
ACET

About MTC MMTec Inc.

MMTEC Inc provides Internet-based technology services and solutions to the Chinese language speaking hedge funds, mutual funds, registered investment advisors, proprietary trading groups, and brokerage firms engaging in securities market transactions and settlements globally. It offers complete suite trading solutions, including services such as fund establishment, issuance, custody, transaction, and settlement. The Company currently has two operating segments, Gujia, MM Future, HC Securities, and MM Global. It generates maximum revenue from the Gujia segment. Gujia segment provides market data services and investor relations management services to customers in China.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: